Summary
The antihypertensive efficacy of a combination of calcium-channel blockers and angiotensin-converting-enzyme (ACE) inhibitors in severe primary hypertension is well known, but a synergistic action of this drug combination in mild to moderate primary hypertension is still not established. Therefore, the sim of the present study was to evaluate the efficacy and telerability of monotherapy with nitrendipine (20 mg) or captopril (100 mg), and of their combination (nitrondipine 10 mg plus captopril 50 mg), in patients suffering from mild to moderate primary hypertension, according to a single-blind, randomized, placebe-controlled design.
After the first 4-week monotherapy period, both nitrendipine and captopril induced a significant decrease in systolic and diastolic blood pressure (BP) (p<0.001). Furthermore, nitrendipine caused a significant increase in heart rate (HR), while no change in HR was observed in patients treated with captopril. Several side effects were observed, both in the nitrendipine-treated patients (facial flushing, headache, malleolar edema) and in the captopril- treated patients (initial hypotension, dizziness, gastrointestinal disorders). However, these side effects were mild and were well tolerated.
In the second combined 4-week therapy period, systolic and diastolic BP of patients treated with 10 mg nitrendipine combined with 50 mg captopril continued to decrease to a degree significantly lower (p<0.001) than that observed at the end of the monotherapy period. Simultaneously, no change in HR values occurred when compared to basal values. Furthermore, the incidence and intensity of some side effects obseryed during the combined therapy period were lower than those of the monotherapy period. These data are in agreement with the hypothesis that the combination of calcium-channel blockers and ACE inhibitors could have a synergistic antihypertensive effect, and, particularly, that the combination of 10 mg nitrendipine and 50 mg captopril appears to be a very effective and well-tolerated regimen for the treatment of mild to moderate primary hypertension.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Guazzi MD, De Cesare N, Galli C, et al. Calcium channel blockade with nifedipine and angiotensin-converting enzyme inhibition with captopril in the therapy of patients with severe primary hypertension. Cireulation 1984;70:279–284.
Pieri R, Nardecchia A, Pirrelli A. Combined nifedipine and captopril treatment in moderately severe primary hypertension. Am J Nephrol 1986;6(Suppl 1):111–114.
MacGregor GA, Markandu ND, Smith SJ et al. Do captopril and nifedipine have an additive effect on blood pressure? 10th Scientific Meeting Int Soc of Hypertension, Interlaken, Switzerland, 1984:568.
Lang R, Degenhardt ST, Ollenschläger G, et al. Effect of low-dose combination nitrendipine/enalapril in less-severe degrees of hypertension. J Cardiovasc Pharmacol 1987;9 (Suppl 4):S254-S255.
Bühler FR, Hulthen L. Calcium channel blockers: Pathophysiologically based antihypertensive treatment concept for the future? Eur J Clin Invest 1982;12:1–9.
Somlyo AP, Somlyo AV. Calcium and magnesium in vascular smooth muscle function. In: GenestJ, KoiwE, KuchelO, eds. Hypertension. New York: McGraw-Hill, 1977:440–466.
Stone PH, Antman EM, Muller JE, et al. Calcium channel blocking agents in the treatment of cardiovascular disorders. Part II: Hemodynamic effects and clinical application. Ann Intern Med 1980;93:886–890.
Fleckenstein A. Specific pharmacology of calcium in myocardium, cardiac pace-makers, and vascular smooth muscle. Ann Rev Pharmacol Toxicol 1977;17:149–156.
Beeler GW Jr, Reuter H. Membrane calcium current in ventricular myocardial fibres. J Physiol 1970;207:191–196.
Lederballe Pedersen O. Calcium blockade as a therapeutic principle in arterial hypertension. Acta Pharmacol Toxicol 1981;49(Suppl 2):1–5.
Bossert F, Vater W. Dihydropyridine, eine neue gruppe stark wirksamer conartherapeuteika. Naturwessenschaften 1971; 58:578–584.
Aoki K, Kondo S, Mochizuki A, et al. Antihypertensive effect of cardiovascular Ca2+-antagonist in hypertensive patients in the absence and presence of beta-adrenergic blockade. Am Heart J 1978;96:218–223.
Kobayashi K, Tarazi RC. Effect of nitrendipine on coronary flow and ventricular hypertrophy in hypertension. Hypertension 1983:5(Suppl 2):45–51.
Puschett JB, Palomino C, Wallia R, et al. The acute effects of nitrendipine on the human kidney. J Cardiovasc Pharmacol 1987;9(Suppl 4):S169-S173.
Thananopavarn C, Sambhi MP, Golub MS, et al. Saluretic and diuretic effects of nitrendipine during antihypertensive monotherapy. Clin Res 1984;32:A340.
Hansson L, Andren L, Oro L, et al. Pharmacokinetic and pharmacodynamic parameters in patients treated with nitrendipine. Hypertension 1983:5(Suppl 2):25–28.
Taburet AM, Singlas E, Colin J-N, et al. Pharmacokinetic studies of nifedipine tablet. Correlation with antihypertensive effects. Hypertension 1983:5(Suppl 2):29–33.
Atkinson AB, Robertson JIS: Captopril in the treatment of clinical hypertension and cardiac failure. Lancet 1979;2:836–839.
Karlberg BE, Asplund J, Nilsson OR, et al. Captopril, an orally active converting enzyme inhibitor, in the treatment of primary hypertension. Acta Med Scand 1981;209:245–252.
De Bruyn JHB, Wenting GJ, Man In't Veld AJ, et al. Captopril affects the blood pressure equally in renovascular and essential hypertension and in the fluid depleted anephric state. Clin Sci 1980:59(Suppl 6):83s-86s.
Vidt DG, Bravo EL, Fouad F. Captopril. N Engl J Med 1982;306:214–218.
Tarazi RC, Bravo EL, Fouad F, et al. Hemodynamic and volume changes associated with captopril. Hypertension 1980;2:576–581.
Fox RH, Goldsmith R, Cushman DW. Bradykinin as a vasodilator in man. J Physiol 1961;157:589–602.
De Jonge A, Wilffert B, Kalkman HO. Captopril impairs the vascular smooth muscle contraction mediated by postsynaptic alpha2-adrenoreceptors in the pithed rat. Eur J Pharmacol 1981;74:385–386.
Kikta D, Fregly MJ. Effect of in vitro administration of captopril on vascular reactivity of rat aorta. Hypertension 1982;4:118–122.
Kazda S, Garthoff B, Knorr A. Nitrendipine and other calcium entry blockers (calcium antagonists) in hypertension. Fed Proc 1983;42:196–201.
Weber MA. A one-year experience with the calcium channel blocking agent, nitrendipine, in patients with essential hypertension: Report of a multicenter study. J Cardiovasc Pharmacol 1987;9(Suppl 4):S182-S189.
Gennari C, Nami R, Bianchini C, et al. Nitrendipine and the angiotensin converting enzyme inhibitors in the treatment of hypertension. J Cardiovasc Pharmacol 1987;9(Suppl 4): S245-S251.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gennari, C., Nami, R., Pavese, G. et al. Calcium-channel blockade (nitrendipine) in combination with ACE inhibition (captopril) in the treatment of mild to moderate hypertension. Cardiovasc Drug Ther 3 (Suppl 1), 319–325 (1989). https://doi.org/10.1007/BF00148477
Issue Date:
DOI: https://doi.org/10.1007/BF00148477